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902TheU.S. PARTNER (Placement
of Aortic Transcatheter Valve)
trial (cohort B) was a randomized
trial of patients with severe aortic
stenosis (AS) who could not have
surgery (1,2). The trial demon-
strated a signiﬁcant survival bene-
ﬁt with transcatheter aortic valve
replacement (TAVR). However,See page 912the mortality at 1 and 2 years,
although substantially lower than
the standard therapy (ST) arm,
remained high (at 30.7% and
43.3%, respectively), reﬂecting the
substantial burden of comorbid-
ities present in this cohort.
Patients can be deemed inop-
erable for surgical aortic valve
replacement (SAVR) based on
clinical comorbidities, frailty, orspeciﬁc technical contraindications such as porcelain aorta,
mediastinal radiation, chest deformities, or the presence of
coronary bypass grafts attached to the chest wall. A sub-
stantial variability in late survival of inoperable patients was
observed according to surgical risk factors in the 2-year
analysis of the randomized PARTNER cohort B (2).
Clinical outcomes may differ according to the reason for
inoperability. We sought to analyze outcomes of inoperable
patients enrolled in the PARTNER cohort B randomized
study and accompanying continued access registry according
to factors that inﬂuenced the decision of inoperability.Methods
Study design and patients. PARTNER 1B was a multi-
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; revised manuscript received August 1, 2013,(aortic valve area <0.8 cm2), with cardiac symptoms (New
York Heart Association [NYHA] class II or higher) who
were considered inoperable, either for clinical or technical
reasons. An as-treated analysis was performed, including
both patients randomized to and treated with TAVR in
the PARTNER 1B trial and patients subsequently treated
in the continued access registry. The PARTNER multi-
center continued access registry was a U.S. Food and Drug
Administration–approved registry that continued after
completion of the randomized trial and had a single arm of
treatment (TAVR). Patients enrolled in this part of the
study had the same entry criteria as for the randomized trial.
The entry criteria were stringent, requiring attestation by
2 cardiac surgeons and an interventional cardiologist
regarding surgical inoperability, deﬁned as a 50% proba-
bility of either death or serious irreversible morbidity after
conventional SAVR. Moreover, this classiﬁcation of inoper-
ability required approval by a central steering committee after
a Web-based presentation by a cardiac surgeon on a weekly
conference call as to the speciﬁc reasons for the declaration of
inoperability. This inoperability was further subclassiﬁed as
technical or clinical through a retrospective review of individual
patient data. Patients were classiﬁed as technically inoperable
(TI) if they had anatomic factors that make the procedural
steps of SAVR either technically impossible or dangerous.
Those patients who were considered to be inoperable
either for clinical reasons or due to a combination of clinical
and technical reasons were deﬁned as clinically inoperable
(CLI). The Society of Thoracic Surgeons (STS) risk score
was used as a measure of clinical risk and comorbidities,
stratifying groups according to STS categories (<5%, 5% to
14.9%, and 15%), broadly deﬁning clinical risk for surgery
as low, intermediate to high, and very high, respectively (2).
Both technical reasons (porcelain aorta, previous bypass graft
beneath the sternum, and chest wall deformity) and some
clinical factors (frailty) for inoperability are not captured by
the STS risk algorithm. The logistic euroSCORE (European
System for Cardiac Operative Risk Evaluation) was also
calculated as a measure of clinical risk for surgery, although
speciﬁc cut-offs were not deﬁned for categorical groups.
Procedure. The Edwards Sapien heart valve system
(Edwards Lifesciences Corporation, Irvine, California) used
in this study comprised a balloon-expandable, stainless steel
stent frame housing a tri-leaﬂet bovine pericardial valve. The
system was mounted on a deﬂectable delivery catheter and
inserted via the common femoral artery under aseptic
conditions as described previously (1).
Analysis according to technical inoperability and clinical
risk. Baseline and procedural characteristics as well as clini-
cal endpoints were studied according to both the dichotomy
of technical versus clinical inoperability and the aforemen-
tioned STS score trichotomy. Thirty-day clinical outcomes
and late outcomes beyond 1 year were studied. The key
endpoints for this analysis were all-cause mortality, cardio-
vascular mortality, stroke, and repeat hospitalization. Repeat
hospitalization was deﬁned as rehospitalization for symptoms
Table 1 Baseline Variables According to Inoperable Category and STS Score
Technically Inoperable
(n ¼ 85)
Clinically Inoperable
(n ¼ 284) p Value
STS <5%
(n ¼ 74)
STS 5%/<15%
(n ¼ 222)
STS 15%
(n ¼ 73) p Value
Age (yrs) 73.4  10.0 (84) 83.6  8.6 (284) <0.0001 71.0  10.4 (74) 82.5  7.8 (221) 88.4  5.6 (73) <0.0001
Male 57.6 (49/85) 47.5 (135/284) 0.1 58.1 (43/74) 49.1 (109/222) 43.8 (32/73) 0.21
BMI (kg/m2) 28.6  6.6 (85) 26.6  7.2 (284) 0.005 29.9  6.5 (74) 26.8  7.4 (222) 25.0  6.1 (73) <0.0001
STS score 5.4  2.9 (85) 12.0  5.8 (284) <0.0001 3.3  1.1 (74) 9.8  2.6 (222) 19.7  4.1 (73) <0.0001
Logistic euroSCORE 14.5  12.0 (84) 26.9  17.2 (279) <0.0001 9.4  8.5 (73) 24.5  14.2 (218) 37.6  19.1 (72) <0.0001
Diabetes 28.2 (24/85) 35.9 (102/284) 0.19 27.0 (20/74) 32.4 (72/222) 46.6 (34/73) 0.03
Hypertension 81.2 (69/85) 86.9 (246/283) 0.19 75.7 (56/74) 87.8 (194/221) 89.0 (65/73) 0.02
NYHA class III and IV 84.7 (72/85) 96.5 (274/284) <0.0001 86.5 (64/74) 94.6 (210/222) 98.6 (72/73) 0.007
Previous PCI 40.0 (34/85) 27.1 (77/284) 0.02 33.8 (25/74) 29.3 (65/222) 28.8 (21/73) 0.74
Previous CABG 37.6 (32/85) 31.4 (89/283) 0.29 20.3 (15/74) 35.7 (79/221) 37.0 (27/73) 0.03
CVD 21.4 (18/84) 26.0 (72/277) 0.4 23.3 (17/73) 24.4 (53/217) 28.2 (20/71) 0.77
PVD 15.7 (13/83) 28.9 (81/280) 0.02 10.8 (8/74) 28.1 (61/217) 34.7 (25/72) 0.002
PHT 34.2 (26/76) 41.2 (96/233) 0.28 28.8 (19/66) 41.0 (77/188) 47.3 (26/55) 0.09
Renal disease* 9.4 (8/85) 19.7 (56/284) 0.03 5.4 (4/74) 13.1 (29/222) 42.5 (31/73) <0.0001
Malignant tumors 43.5 (37/85) 26.4 (74/280) 0.003 44.6 (33/74) 25.1 (55/219) 31.9 (23/72) 0.007
Liver disease 1.2 (1/85) 4.9 (14/283) 0.21 6.8 (5/74) 3.6 (8/222) 2.8 (2/72) 0.41
COPD 25.9 (22/85) 50.4 (143/284) <0.0001 37.8 (28/74) 45.5 (101/222) 49.3 (36/73) 0.35
Anemia 43.5 (37/85) 71.0 (201/283) <0.0001 51.4 (38/74) 62.9 (139/221) 83.6 (61/73) 0.0002
Values are mean  SD (n) or % (n/N). *Creatinine 2 mg/dl.
BMI ¼ body mass index; CABG ¼ coronary artery bypass grafting; COPD ¼ chronic obstructive pulmonary disease; CVD ¼ cerebrovascular disease; euroSCORE ¼ European System for Cardiac Operative Risk Evaluation; NYHA ¼ New York Heart Association;
PCI ¼ percutaneous coronary intervention; PHT ¼ pulmonary hypertension; PVD ¼ peripheral vascular disease; STS ¼ Society of Thoracic Surgeons.
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Table 2
Comparison of Baseline QOL Scores According to
Inoperability Category
Raw Mean Value
p ValueTechnical Clinical
KCCQ
Summary 45.18  20.99 35.12  19.85 <0.001
Physical limitations 49.86  24.71 30.55  24.04 <0.001
Total symptoms 56.92  21.34 47.35  22.09 <0.001
Self-efﬁcacy 81.85  19.73 76.78  22.43 0.064
QOL 35.61  19.46 33.18  21.29 0.35
Social limitation 38.59  30.51 28.15  26.32 0.003
SF-12
Physical 30.60  8.01 28.57  7.16 0.033
Mental 48.46  10.32 44.44  11.77 0.006
Values are mean  SD.
KCCQ ¼ Kansas City Cardiomyopathy Questionnaire; QOL ¼ quality of life; SF-12 ¼ Medical
Outcomes Study Short-Form 12-Item Health Survey.
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904of AS and/or complications of the valve procedure. These
endpoints for TI and CLI patients were placed in context
through a comparison with patients recruited in the PART-
NER 1B study receiving ST by using an as-treated analysis.
Quality of life assessment. Health status, which includes
symptoms, functional status, and quality of life (QOL), was
evaluated with standardized written questionnaires pre-
procedure and at 1, 6, and 12 months post-procedure (3).
Follow-up questionnaires were administered during in-
person visits to the enrolling centers or by mail. Disease-
speciﬁc health status was assessed from the patient’s
perspective by using the Kansas City Cardiomyopathy
Questionnaire (4), and generic health status was evaluated
with the Medical Outcomes Study Short-Form 12-Item
Health Survey (SF-12) (5). Other details of the QOL
analyses performed have been described previously (3).
Statistical analysis. Categorical variables, presented as
frequencies with their respective percentages, were compared
by using the Fisher exact test. Continuous variables, presented
as mean  SD, were compared by using the Student t test.
Survival curves for time-to-event variables were constructed
on the basis of all available follow-up data with the use of
Kaplan-Meier estimates and were compared by using the
log-rank test. Patients were censored according to the time
of their last known follow-up. A 2-sided alpha level of 0.05
was used for superiority testing. Given the as-treated analysis,
the start date for TAVR patients was the date of the proce-
dure; for ST patients, it was the date of randomization.
A multivariable analysis for 2-year mortality in the TAVR
patients was performed by using a Cox regression model with
forward stepwise analysis. The multivariable analysis incor-
porated baseline clinical variables related to 2-year mortality
with a signiﬁcance level of p 0.1; this included randomized
study versus continued access, age, body mass index (BMI),Figure 1 Technical and Clinical Causes of Inoperability
The underlying reasons are shown in pie chart format for (A) technical inoperability and
a hierarchical breakdown represented (inset box for A and B, respectively). BMI ¼ body m
fraction; STS ¼ Society of Thoracic Surgeons.chronic obstructive pulmonary disease (COPD), major
arrhythmia, NYHA class III and IV, angina, anemia,
peripheral vascular disease, porcelain aorta, aortic valve mean
gradient at baseline, TI, and STS risk score (as a continuous
variable). QOL analyses, comparing the TI and CLI TAVR
groups, were performed by using an analysis of covariance to
adjust for baseline differences between groups. All statistical
analyses were performed by using SAS version 9.2 (SAS
Institute, Inc., Cary, North Carolina).
Results
Patients and baseline characteristics. A total of 369 pa-
tients were treated with TAVR, including 175 from the
randomized study and 194 from the continued access registry.
Among these, 85 patients (23.0%) were not operated on for
technical reasons alone and 284 (77.0%) were CLI; 34 of the(B) clinical inoperability. Those with multiple technical or clinical reasons have
ass index; CABG ¼ coronary artery bypass grafting; Cr ¼ creatinine; EF ¼ ejection
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905latter were inoperable for a combination of clinical and
technical reasons. A total of 181 patients received ST.
When stratiﬁed according to STS score, 74 (20.0%), 222
(60.2%), and 73 (19.8%) had STS scores <5%, 5% to
14.9%, and 15%, respectively. For CLI, 32 (11.3%), 179
(63.0%), and 73 (25.7%) had STS scores <5%, 5% to
14.9%, and 15%. In the TI group, 42 (49.4%) and 43
(50.6%) had STS scores <5% and 5% to 14.9%, respectively;
no TI patients had STS scores 15%.
A total of 366 patients (99.2%) completed clinical follow-
up to 1 year and 347 (94.0%) to 2 years. Patients not
operated on for technical reasons alone, compared with
patients not operated on for other (clinical) reasons, were
younger, were less likely to be in NYHA class III or IV, and
had lower STS scores and logistic euroSCORE ﬁndings
(Table 1). They were more likely to have higher BMI values
and a history of previous malignancy and previous percuta-
neous coronary intervention and less likely to have
peripheral vascular disease, chronic kidney disease, COPD,
and anemia. The excess of malignancy in the TI versus the
CLI group (43.5% vs. 26.4%) was commensurate with the
25% of TI patients who were inoperable for a “hostile chest”
related to previous chest wall radiation. TI patients had
better QOL scores at baseline than CLI patients (Table 2).
Considering the entire TAVR cohort, patients with lower
STS risk scores were younger, had higher BMI values, and
were less likely to be diabetic, hypertensive, and in NYHA
class III or IV (Table 1). They had less peripheral vascular
disease, previous coronary artery bypass grafting, renal
disease, and anemia.
Underlying reasons for technical and clinical inoper-
ability. Site-reported underlying technical causes for inop-
erability included porcelain aorta, deﬁned as near or
complete circumferential calciﬁcation of the ascending aorta
and/or aortic arch precluding safe cross-clamping or can-
nulation of the aorta or requiring circulatory arrest with
ascending aorta/arch replacement. Other reasons included
chest wall radiation, chest wall deformity, bypass grafts close
to the sternum creating a potentially hostile re-entry, an
absent or reconstructed sternum (Fig. 1), and other causes,
including mediastinal adhesions (1 after 3 previous cardiac
surgeries and 2 on aborted SAVR), a right ventricle adherent
to the sternum, a case with recurrent fungal mediastinitis
requiring multiple sternotomies after previous cardiac
surgery, a case with a previous pneumonectomy and severely
distorted mediastinal/thoracic anatomy, or a combination of
the aforementioned factors (“multiple technical reasons”
[further detailed in Fig. 1]). Underlying clinical causes of
inoperability were multiple comorbidities, frailty, severe
lung disease, and others (including poor left and right
ventricular function, neurological disease, and pulmonary
hypertension).
Clinical outcomes. The duration of postprocedure
hospital stay was marginally shorter in TI patients versus
CLI patients undergoing TAVR (5.34  2.18 days vs. 5.86
 1.97 days; p ¼ 0.04). There were no other signiﬁcant
Table 4 30-Day Outcomes (Kaplan-Meier Analysis) According to Inoperability Category and STS Score
Technically Inoperable
(n ¼ 85)
Clinically Inoperable
(n ¼ 284) p Value
STS <5%
(n ¼ 74)
STS 5%/<15%
(n ¼ 222)
STS 15%
(n ¼ 73)
p Value
Across Groups
Death
From any cause 4.7% (4) 8.8% (25) 0.22 4.1% (3) 7.2% (16) 13.7% (10) 0.076
From cardiovascular cause 3.6% (3) 7.8% (22) 0.18 1.4% (1) 7.2% (16) 11.0% (8) 0.063
Repeat hospitalization 6.0% (5) 8.3% (22) 0.54 4.1% (3) 7.1% (15) 13.9% (9) 0.096
Death from any cause or repeat
hospitalization
10.6% (9) 16.5% (47) 0.19 8.1% (6) 14.0% (31) 26.0% (19) 0.0066
Stroke or TIA 3.6% (3) 4.7% (13) 0.66 5.4% (4) 3.7% (8) 5.6% (4) 0.69
TIA 0.0% (0) 0.4% (1) 0.58 0.0% (0) 0.5% (1) 0.0% (0) 0.72
Stroke 3.6% (3) 4.3% (12) 0.76 5.4% (4) 3.3% (7) 5.6% (4) 0.54
Major 3.6% (3) 3.2% (9) 0.89 5.4% (4) 2.3% (5) 4.2% (3) 0.38
Minor 0.0% (0) 1.1% (3) 0.34 0.0% (0) 0.9% (2) 1.4% (1) 0.63
Myocardial infarction 0.0% (0) 0.7% (2) 0.44 0.0% (0) 0.5% (1) 1.4% (1) 0.50
Hemorrhagic event 13.0% (11) 20.2% (57) 0.13 15.0% (11) 18.5% (41) 22.3% (16) 0.53
Major bleeding 10.6% (9) 14.9% (42) 0.32 13.6% (10) 13.1% (29) 16.9% (12) 0.78
Minor bleeding 2.4% (2) 6.0% (17) 0.18 1.4% (1) 5.9% (13) 6.9% (5) 0.24
Vascular complications 17.6% (15) 25.5% (72) 0.14 14.9% (11) 25.8% (57) 26.2% (19) 0.14
Major 5.9% (5) 9.5% (27) 0.3 6.8% (5) 9.0% (20) 9.6% (7) 0.80
Permanent pacemaker 5.9% (5) 3.3% (9) 0.26 8.2% (6) 3.2% (7) 1.4% (1) 0.083
Renal failure (dialysis required) 1.2% (1) 2.9% (8) 0.37 0.0% (0) 1.9% (4) 7.2% (5) 0.013
Values are % (n).
TIA ¼ transient ischemic attack; other abbreviation as in Table 1.
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906differences in periprocedural (Table 3) or 30-day (Table 4)
outcomes in the TI versus CLI cohorts. Differences in
outcomes emerged as early trends with statistical signiﬁ-
cance later, with lower all-cause mortality at both 1 year
(14.1% vs. 32.0%; p ¼ 0.002) and 2 years (23.1% vs.
43.8%; p ¼ 0.001) in the TI group versus the CLI group
(Fig. 2). At 2 years, the mortality (67.4%) and cardiac
mortality (44.1%) in the ST arm was signiﬁcantly greater
than both TI (p < 0.0001) and CLI (p < 0.0001) patients.
Similarly, repeat hospitalization was 70.0% for ST patients
versus 20.3% and 29.0% for TI and CLI TAVR patients,
respectively (p < 0.0001 for each comparison). Although
there was a numerically higher rate of stroke at 2 years’
postprocedure in the CLI TAVR patients (8.5%), there was
no difference in TI TAVR patients (4.8%) versus ST
patients (5.4%) (p ¼ NS for the 3 groups). Of the CLI
patients, 34 also had technical reasons for inoperability.
These patients had a 2-year mortality (43.8%) similar to
those who were inoperable for clinical reasons alone
(43.3%) (p ¼ NS). However, these patients with a combi-
nation of clinical and additional technical reasons for
inoperability had more emergent conversion to open heart
surgery during the TAVR procedure (5.9% vs. 0.4%;
p ¼ 0.003), late stroke or transient ischemic attack (22.2%
vs. 8.9%; p ¼ 0.048), and myocardial infarction (6.7% vs.
0.4%; p ¼ 0.0043) than those who were inoperable for
clinical reasons alone.
After clinical risk stratiﬁcation of TAVR patients
according to the STS score (Table 4), patients with lower
STS scores were more likely to develop renal failure at 30
days (p ¼ 0.0129). However, there was no difference in the
incidence of 30-day stroke rates (5.4% with STSscores <5%; 3.3% with STS scores 5% to 14.9%, and 5.6%
with STS scores 15%; p ¼ 0.54 across groups). For later
(2-year) outcomes, both all-cause and cardiovascular
mortality were signiﬁcantly lower in the group with STS
scores <5% (Fig. 3).
Functional outcomes and QOL. Clinical reasons for
inoperability was associated with increased baseline hazard
for severe symptomatic heart failure (NYHA class III and
IV) compared with technical reasons (1.14 [95% conﬁ-
dence interval (CI): 1.04 to 1.25]; p < 0.0001]). The
hazard for persistent severe symptomatic heart failure
increased to 1.48 (95% CI: 1.06 to 2.08; p ¼ 0.01) at
discharge, 1.86 (95% CI: 1.12 to 3.09; p ¼ 0.01) at 30
days, 2.49 (95% CI: 1.01 to 6.13; p ¼ 0.03) at 6 months,
and 2.32 (95% CI: 1.10 to 4.89; p ¼ 0.02) at 1 year. At 1
year, persistent severe symptomatic heart failure was
present in 24.6% of patients with clinical reasons for
inoperability and 10.6% of patients with technical reasons
alone (Fig. 4). Even after adjusting for baseline, follow-up
QOL scores on both the Kansas City Cardiomyopathy
Questionnaire and the SF-12 were higher among the TI
group compared with the CLI group (Table 5). QOL
measures, adjusted relative to baseline, showed a signiﬁ-
cantly greater improvement in TI patients versus CLI
patients. The differences were seen across all measures but
were most sustained in the physical measures of QOL.
Independent predictors of late mortality. In the multi-
variable model for 2-year mortality (Table 6), higher STS
score (hazard ratio [HR]: 1.03 [95% CI: 1.00 to 1.06];
p ¼ 0.0466) was a signiﬁcant independent predictor of
all-cause mortality, as was clinical inoperability (HR: 1.85
[95% CI: 1.12 to 3.12]; p ¼ 0.0166). Conversely stated,
Figure 2 Key Endpoints According to Technical Versus Clinical Inoperability in the Context of Standard Therapy
Kaplan-Meier curves are shown with (A) death, (B) cardiac death, (C) repeat hospitalization, and (D) stroke.
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907technical inoperability was independently protective (HR:
0.54 [95% CI: 0.32 to 0.89]; p ¼ 0.0166). Because the
STS score was generally low in TI patients, the STS score
had prognostic relevance primarily in the CLI patients
(Table 7), in whom greatest survival was seen in those with
the lower STS scores. TI patients with low and intermediate
STS scores had similar survival.
Discussion
The present study produced several salient ﬁndings. First,
there was a signiﬁcant heterogeneity in the reasons for
inoperability in patients with severe AS undergoing
TAVR. In the TI group, the most common reason was
porcelain aorta followed by “hostile chest,” predominantly
associated with previous radiation exposure. In the CLI
group, multiple comorbidities, frailty, and lung diseasewere common. Second, although these factors had only
a small inﬂuence on early outcomes, they had a signiﬁcant
bearing on 2-year outcomes. In the subset deemed inop-
erable solely based on technical reasons (approximately
one-quarter of all inoperable patients), 2-year outcomes
after TAVR were excellent, with mortality one-half that of
CLI patients (23.3% vs. 43.8%; p < 0.0001). Third,
although the CLI group had worse clinical outcomes
overall, there was signiﬁcant heterogeneity with 2-year
mortality increasing progressively with increasing STS
score, a risk score based on early mortality after conven-
tional surgery (Table 7). These outcomes were still better
than those receiving ST (43.8% vs. 67.4% at 2 years;
p < 0.001). Finally, there were also substantial differences
in QOL according to type of inoperability, with more
substantial improvements in those with technical rather
than clinical reasons for inoperability.
Figure 3 Key Endpoints According to STS Score Groups (Kaplan-Meier Curves)
Kaplan-Meier curves are shown with (A) death, (B) cardiac death, (C) repeat hospitalization, and (D) stroke. The STS risk score was used as a measure of clinical risk and
comorbidities, stratifying groups according to STS categories: low, STS score <5%; intermediate to high, STS score 5% to 14.9%; and very high, STS score 15. Abbreviation as
in Figure 1.
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TAVR has shown outcomes superior to ST in inoperable
patients (1,2) and noninferiority to surgery in high-risk
operable patients (6,7). Patients with technical reasons
alone for inoperability frequently have a much lower clinical
risk proﬁle (on average, 10 years younger with [among other
differences] one-half the frequency of renal failure and
COPD) (Table 1). In the absence of clinical reasons of
inoperability, they have better outcomes than the remainder
of the inoperable population.
Our ﬁndings are similar to those of a Canadian registry
(8), which reported that porcelain aorta, the most common
cause of technical inoperability in the present series, is
associated with similar procedural outcomes and better
2-year outcomes than those without porcelain aorta.
Conversely, a German registry of self-expanding TAVRreported worse acute outcomes in patients with porcelain
aorta (9). These patients, however, had more comorbidities
in their porcelain aorta cohort. Thus, one may speculate that
the TI cohort most likely had better clinical outcomes not
due to the presence of technical reasons of inoperability
but rather to the absence of clinical reasons for inoperability.
Moreover, this German registry used access approaches
other than the transfemoral approach. In the present series,
although the TI group had the best clinical outcome data,
cases from the CLI group whose inoperability was com-
pounded with technical reasons did worse than TI patients
but also worse compared with CLI patients who had no
additional technical reasons for inoperability, most notably
with more cerebrovascular events.
Clinical inoperability in the context of standard therapy.
Overall, mortality (all-cause and cardiac) for CLI TAVR
Figure 4 Symptoms of Heart Failure According to Inoperability Criteria
Changes in the frequency of persistent severe symptoms of heart failure (New York Heart Association [NYHA] III and IV) with time are shown according to technical or clinical
reasons for inoperability.
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909patients was intermediate between those of the TI TAVR
patients and patients receiving ST (Fig. 2). Repeat hospi-
talization after TAVR in the CLI group was signiﬁcantly
better than ST (70.0% vs. 29.0%; p < 0.0001). Among CLI
patients undergoing TAVR, there are attenuated gains
relative to TI patients, in that there was lower survival and
a trend to higher stroke. Patients in the CLI group with an
STS score 15% carried a high mortality (42.5% at 1 year
and 52.6% at 2 years). This ﬁnding is in line with the
previous stipulation that TAVR may have limited value in
some patients; namely, those at the higher end of the
surgical risk (2).
The STS score and further stratiﬁcation of survival.
Given considerable degrees of variation in the assessment of
clinical criteria for inoperability, further stratiﬁcation of this
clinical risk is an important factor in decision making for
treatment.Ananalysis of randomizedpatients in cohortBof the
PARTNER trial demonstrated increasing 2-year mortality
with increasing STS score (2). The present study corroborates
these data in a larger cohort.
Although the comparison of SAVR with TAVR in
intermediate and low clinical risk groups mandates ran-
domized trial data, outcomes were observed in TI patients
similar to those reported in surgery in patients of similarly
low/intermediate clinical risk. The mean age of those
inoperable for technical reasons alone was 73.4  10.0
years, and the mean STS score was in the low to inter-
mediate range (5.4  2.9). In this population, the 30-day
mortality was 4.7%, 1-year mortality was 14.1%, and2-year mortality was 23.3%. Wendt et al. (10) reported
mid-term data in patients undergoing SAVR; in an
intermediate-risk group with an STS score of 6.5  3.8,
the 1-year mortality was 13.9% at 1 year and 19.2% at 2
years, comparable to that seen in the present study in TI
patients. Arguably, the TI cohort data provide a preview of
the impact of intermediate-level comorbidities on the out-
comes of TAVR. The PARTNER II and SURTAVI
(Surgical Replacement and Transcatheter Aortic Valve
Implantation) trials are ongoing and should provide a
deﬁnitive comparison of TAVR and surgery in interme-
diate surgical risk populations.
QOL and symptoms of heart failure. Taking the inop-
erable TAVR cohort as a whole, at 12 months, TAVR
patients reported higher SF-12 physical and mental health
scores compared with ST patients, with a difference of 5.7
and 6.4 points, respectively (p < 0.0001 for both compari-
sons) (3). There were clear differences in QOL improve-
ment relative to baseline; there was a substantially better
improvement in the SF-12 physical score in TI but no
difference in the SF-12 mental score at 12 months after
TAVR (Table 5). This disparity may be accounted for by the
coexistence of respiratory disease and frailty (with associated
symptoms of fatigue) prevalent in the CLI population.
Similarly, despite an improvement in symptoms of heart
failure in both TI and CLI patients, one-quarter of CLI
patients had persistent substantial symptoms of heart failure
(NYHA class III and IV) at follow-up versus one-tenth of
TI patients.
Table 5 QOL at Follow-Up According to Reasons for Inoperability
Adjusted Mean Value Mean Difference
p Value
Technically Inoperable
(n ¼ 85)
Clinically Inoperable
(n ¼ 284) (Technical – Clinical) 95% CI
KCCQ summary
1 month 68.7 (63.3 to 74.2) 59.9 (56.8 to 63.1) 8.8 (2.4 to 15.2) 0.007
6 months 76.4 (71.3 to 81.4) 69.1 (66.0 to 72.2) 7.3 (1.3 to 13.3) 0.02
12 months 74.9 (69.0 to 80.9) 66.8 (63.0 to 70.7) 8.1 (0.9 to 15.2) 0.02
KCCQ physical limitations
1 month 64.1 (57.7 to 70.6) 52.7 (48.6 to 56.7) 11.5 (3.7 to 19.2) 0.004
6 months 72.0 (65.2 to 78.8) 58.4 (54.2 to 62.7) 13.5 (5.3 to 21.7) 0.001
12 months 69.1 (62.6 to 75.7) 55.7 (51.1 to 60.4) 13.4 (5.1 to 21.7) 0.002
KCCQ total symptoms
1 month 73.8 (68.8 to 78.8) 67.1 (64.2 to 70.1) 6.6 (0.8 to 12.5) 0.03
6 months 79.4 (74.5 to 84.4) 74.5 (71.5 to 77.5) 4.9 (0.9 to 10.8) 0.10
12 months 78.0 (72.2 to 83.8) 72.3 (68.6 to 76.0) 5.7 (1.3 to 12.6) 0.11
KCCQ self-efﬁcacy
1 month 87.9 (83.7 to 92.0) 84.3 (81.9 to 86.7) 3.6 (1.2 to 8.4) 0.14
6 months 90.2 (86.4 to 94.0) 86.4 (84.1 to 88.7) 3.8 (0.7 to 8.3) 0.095
12 months 85.2 (80.6 to 89.8) 85.3 (82.3 to 88.3) 0.1 (5.6 to 5.4) 0.98
KCCQ QOL
1 month 73.0 (67.1 to 79.0) 62.7 (59.3 to 66.2) 10.3 (3.4 to 17.2) 0.003
6 months 81.2 (75.9 to 86.4) 74.1 (70.9 to 77.3) 7.1 (0.9 to 13.3) 0.02
12 months 78.6 (72.1 to 85.1) 72.7 (68.5 to 76.9) 5.9 (1.9 to 13.7) 0.14
KCCQ social limitation
1 month 64.9 (57.2 to 72.5) 52.4 (47.6 to 57.2) 12.4 (3.3 to 21.6) 0.008
6 months 76.7 (69.2 to 84.3) 66.0 (61.1 to 70.9) 10.7 (1.7 to 19.8) 0.02
12 months 73.6 (65.6 to 81.7) 61.4 (55.8 to 66.9) 12.2 (2.4 to 22.1) 0.02
SF-12 physical
1 month 37.5 (35.3 to 39.7) 33.8 (32.5 to 35.0) 3.7 (1.1 to 6.3) 0.005
6 months 41.2 (38.9 to 43.5) 33.9 (32.5 to 35.4) 7.3 (4.5 to 10.0) <.0001
12 months 39.7 (37.1 to 42.3) 34.7 (33.0 to 36.4) 5.0 (1.9 to 8.2) 0.002
SF-12 mental
1 month 51.1 (48.4 to 53.8) 47.7 (46.1 to 49.3) 3.4 (0.2 to 6.5) 0.04
6 months 52.4 (49.9 to 55.0) 51.0 (49.5 to 52.6) 1.4 (1.6 to 4.4) 0.36
12 months 52.8 (50.3 to 55.3) 52.3 (50.7 to 53.9) 0.5 (2.5 to 3.4) 0.76
Comparison of mean scores over time from analysis of covariance, adjusting for baseline.
CI ¼ conﬁdence interval; other abbreviations as in Table 2.
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clinical team treating the patient for the underlying cause of
inoperability. However, the labeling of inoperability re-
quired agreement by 2 cardiac surgeons and a joint case
presentation, including demonstration of computedTable 6
Multivariable Cox Regression Model for
2-Year All-Cause Mortality
Hazard Ratio (95% CI) p Value
Technically inoperable* 0.54 (0.32–0.89) 0.017
STS risk score 1.03 (1.00–1.06) 0.047
BMI (kg/m2) 0.95 (0.92–0.97) 0.0003
COPD 1.46 (1.04–2.06) 0.030
Multivariable predictors using stepwise Cox regression with entry/stay criteria of 0.1/0.1; variables
included randomized study versus continued access, age, BMI, COPD, major arrhythmia, NYHA
class III and IV, angina, anemia, PVD, porcelain aorta, aortic valve mean gradient at baseline,
technical inoperability (i.e., not operated on for technical reasons alone), and STS risk score (as
a continuous variable). *When conversely stated, clinical inoperability hazard ratio was 1.85 (95%
CI: 1.12 to 3.12), p ¼ 0.0166.
Abbreviations as in Table 1.tomography images if a porcelain aorta was diagnosed.
Reasons for inoperability were not studied in ST patients,
limiting the validity of direct comparisons with TI/CLI
TAVR subgroups separately. The ST group was from the
PARTNER B randomized cohort alone, whereas the TAVR
group included both randomized and continued access
patients, introducing a potential bias in the TAVR group.
However, to account for this possible bias, randomized versus
nonrandomized status was introduced as a variable in the
multivariable model for TAVR 2-year mortality and was not
signiﬁcant in the model. Frailty was not objectively deﬁned
or captured. Moreover, symptoms were analyzed by using
a subjective scale. This was a retrospective analysis of
subgroups that were not prespeciﬁed.
In this study of an early-generation, balloon-expandable
TAVR device, vascular complications were frequently seen
in close to 18% of the TI patients and >25% of the CLI
patients. These rates are high, and the reduction in device
proﬁle with further device iterations is likely to contribute to
Table 7
The Interaction of Inoperability Category and
STS Score on Mortality
Technically Inoperable Clinically Inoperable p Value
30-day mortality
STS <5% 4.8% (2) 3.1% (1) 0.73
STS 5%/<15% 4.7% (2) 7.8% (14) 0.47
STS 15% – 13.7% (10) NA
p value 0.99 0.16
1-year mortality
STS <5% 12.0% (5) 12.7% (4) 0.99
STS 5%/<15% 16.3% (7) 31.2% (55) 0.06
STS 15% – 42.5% (31) NA
p value 0.57 0.009
2-year mortality
STS <5% 22.4% (8) 20.5% (6) 0.82
STS 5%/<15% 24.4% (10) 44.2% (74) 0.03
STS 15% – 52.6% (38) NA
p value 0.73 0.008
NA ¼ not applicable; other abbreviation as in Table 1.
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911an ongoing improvement in TAVR outcomes. Similarly, the
other prognostically important complication of paravalvular
leak is likely to be attenuated by advances in device and
procedural planning.
Conclusions
The identiﬁcation of different risk subsets within the
inoperable TAVR population is an important observation
for patient selection for the procedure. Patients with severe
calciﬁc AS deemed inoperable for technical reasons alone
have lower risk proﬁles and longer survival with greater
improvements in QOL that make them excellent candidates
for TAVR. In contrast, patients inoperable for clinical
reasons are a heterogeneous group whose outcomes after
TAVR seem reasonable compared with ST but inferior to
those of TI patients.Reprint requests and correspondence: Dr. Raj R. Makkar,
Cedars-Sinai Heart Institute, Advanced Health Sciences Pavillion,
127 S. San Vicente Boulevard, Suite A3600, Los Angeles,
California 90048. E-mail: Raj.Makkar@cshs.org.REFERENCES
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